Scientific article
English

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients

Published in

Transplantation, vol. 74, no. 7, p. 1000-1006

Publication date

2002

Abstract

Posttransplant Epstein-Barr virus-associated B-cell lymphoproliferative disease (PTLD) has a higher incidence after intestinal transplantation than after transplantation of other solid organs and is associated with a high mortality. A new anti-CD20 monoclonal antibody, rituximab, has shown efficiency in the treatment of B-cell lymphoma, including PTLD, but its use has not yet been reported in intestinal transplant recipients.

Keywords

  • Adult
  • Antibodies, Monoclonal/adverse effects/therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents/adverse effects/therapeutic use
  • Child
  • Child, Preschool
  • Epstein-Barr Virus Infections/complications
  • Female
  • Graft Rejection/drug therapy
  • Humans
  • Immunosuppressive Agents/administration & dosage/therapeutic use
  • Infant
  • Intestines/transplantation
  • Lymphoma/virology
  • Lymphoproliferative Disorders/drug therapy/etiology/virology
  • Male
  • Middle Aged
  • Muromonab-CD3/therapeutic use
  • Organ Transplantation/adverse effects
  • Retrospective Studies
  • Treatment Outcome

Citation (ISO format)

BERNEY, Thierry et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. In: Transplantation, 2002, vol. 74, n° 7, p. 1000–1006. doi: 10.1097/01.TP.0000031931.31954.53

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0041-1337
548views
0downloads

Technical informations

Creation

20/01/2015 15:47:00

First validation

20/01/2015 15:47:00

Update

14/03/2023 22:44:31

Status update

14/03/2023 22:44:30

Last indexation

30/10/2024 22:26:37
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated